ABBOTINDIA25,230.00

Abbott India Ltd.

· Pharma & Health
₹ CrorePeersPFIZERGLAXOIPCALABAJANTPHARMANTHEMMEDANTAGLENMARKBIOCON
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
2Y
CAGR
Revenue+8.1+8.8
EBITDA+11.7+14.1
Net Income+9.7+13.7
Total Assets+9.9+11.9
Total Equity+12.8+13.6
Free Cash Flow+30.4+4.3
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.